15,428
edits
Changes
Jump to navigation
Jump to search
→Apligraph Oral: Update URL.
|url=http://www.organogenesis.com/about_us/headquarters.html
|accessdate=2011-03-06
}}</ref> They profit from [[Apligraf]], which is a synthetic [[skin ]] created from harvested foreskins.<ref name='Organogenesis 2011'>{{REFweb
|quote=Human keratinocytes and fibroblasts are derived from neonatal foreskins.
|last=
{{Citation
|Title=We Must Be Able To Obtain Adequate Sources Of Supply
|Text=We manufacture Apligraf for commercial sale, as well as for use in clinical trials, at our Canton, Massachusetts facility. Among the fundamental raw materials needed to manufacture Apligraf are keratinocyte and fibroblast cells. Because these cells are derived from donated infant [[foreskin]], they may contain human-borne pathogens. We perform extensive testing of the cells for pathogens, including the [[HIV]] or "[[AIDS]]" virus. Our inability to obtain cells of adequate purity, or cells that are pathogen-free, would limit our ability to manufacture sufficient quantities of our products.
|Author=
|Source=Organogensis
== Apligraph Oral ==
Organogenesis is presently seeking [[FDA]] approval for Apligraph Oral, a [[foreskin]]-derived product for the "treatment of surgically treated gingival and alveolar mucosal surface defects in adults."<ref>{{REFweb
|last=
|first=
|date=2011-11-17
|title=November 17, 2011: Cellular, Tissue and Gene Therapies Advisory Committee Meeting: Transcript
|url=httphttps://www.fda.gov/downloadsadvisory-committees/AdvisoryCommitteesadvisory-committee-calendar/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM284112.pdfcellular-tissue-and-gene-therapies-advisory-committee-september-2-3-2021-meeting-announcement
|publisher=
|accessdate=20112021-1209-2002
}}</ref>
[[Category:Company]]
[[Category:Financial gain]]
[[Category:Foreskin product]]
[[Category:From CircLeaks]]